Article 101

Article originally published in the Cross-border Life Sciences Handbook 2006/07

Pharmaceutical and biotech companies are turning with increasing frequency to in-licensing and collaboration agreements – pharmaceutical companies to put new products in their pipelines and biotech companies to access the resources needed for final-stage development, clinical trials, manufacturing, and distribution. One result of the increasing